Insurance Journal

OCTOBER 7, 2024

Supreme Court declined on Monday to hear former pharmaceutical company CEO Martin Shkreli’s challenge to a $64.6 million financial penalty imposed by a judge after he raised a lifesaving drug’s price by more than 4,000%. The justices turned …

Pharmaceuticals 102

Pharmaceuticals 102

IP Watchdog

APRIL 3, 2023

The Information Technology and Innovation Foundation (ITIF) is hosting an event on the downfall of Japan’s pharmaceutical industry. This week in Washington IP news, Congress is out of town thanks to a state work period, but there are still several interesting events related to the IP world.

Pharmaceuticals 59

Pharmaceuticals Technology 59

IP Watchdog

OCTOBER 28, 2024

Patent and Trademark Office (USPTO), whose “Drug Patent and Exclusivity Study” effectively debunks the false narratives and bogus statistics that have been levied against pharmaceutical patents with significant effect in recent years.

Pharmaceuticals 114

Pharmaceuticals Technology 114

Insurance Journal

SEPTEMBER 3, 2024

decreased across the automotive, consumer product, food and drink, medical device and pharmaceutical industries in the second quarter, according to a new report from Sedgwick. Product recalls in the U.S. Sedgwick’s U.S. Recall Index found the 788 recalls across those …

Automotive 112

Automotive Pharmaceuticals 112

IP Watchdog

JUNE 25, 2024

Court of Appeals for the Federal Circuit (CAFC) issued a precedential decision today reversing a district court’s grant of Hikma Pharmaceuticals’ motion to dismiss Amarin Pharma, Inc.’s s complaint against it for induced infringement.

Pharmaceuticals 111

Pharmaceuticals Litigation 111

IP Watchdog

SEPTEMBER 16, 2024

Last week, Patients for Affordable Drugs (“P4AD”) became the latest amicus to file a brief with the U.S. Court of Appeals for the Third Circuit in Bristol Myers Squibb Co. Becerra et al.

Pharmaceuticals 64

Pharmaceuticals Manufacturing Litigation 64

IP Watchdog

NOVEMBER 6, 2023

Court of Appeals for the Federal Circuit (CAFC) issued a precedential decision in Actelion Pharmaceuticals Ltd. Mylan Pharmaceuticals Inc. Today, the U.S. vacating an infringement judgment against Mylan in the Northern District of West Virginia.

Evidence 105

Evidence Pharmaceuticals Construction Litigation 105

IP Watchdog

NOVEMBER 4, 2024

the biological, chemical, and pharmaceutical arts) and “predictable arts” (e.g., The case law distinguishes between so-called “unpredictable arts” (e.g., electrical and mechanical arts) for purposes of Section 112 analysis for the very reason that one is considered “predictable” while the other, “unpredictable.”

Pharmaceuticals 59

Pharmaceuticals Case Law Litigation 59

IP Watchdog

AUGUST 24, 2022

On August 19, British brand name pharmaceutical firm GlaxoSmithKline (GSK) filed a brief with the U.S. Supreme Court opposing a petition for writ of certiorari filed by generic drugmaker Teva Pharmaceuticals. Teva’s petition appeals a decision by the U.S.

Pharmaceuticals 126

Pharmaceuticals Litigation 126

IP Watchdog

JUNE 5, 2024

Chamber of Commerce’s Global Innovation Policy Center (GIPC), the Pharmaceutical Research and Manufacturers of America (PhRMA) and the Council for Innovation Promotion (C4IP) are among a number of organizations that have recently submitted comments on the U.S.

Pharmaceuticals 113

Pharmaceuticals Manufacturing 113

IP Watchdog

NOVEMBER 9, 2023

On October 7, the Federal Trade Commission (FTC) sent letters to 10 pharmaceutical companies notifying them of the agency’s intent to challenge allegedly improper patent listings in the U.S. Food and Drug Administration’s (FDA) Orange Book.

Pharmaceuticals 122

Pharmaceuticals 122

Insurance Journal

SEPTEMBER 9, 2024

Scott announced that one week before its trial is to begin, the city has reached an $80 million settlement with Teva Pharmaceuticals to resolve the city’s claims over the firm’s role in fueling Baltimore’s opioid epidemic. Mayor Brandon M. Teva …

Pharmaceuticals 59

Pharmaceuticals Litigation 59

IP Watchdog

NOVEMBER 13, 2024

The petition was filed on September 11, 2024, by Salix Pharmaceuticals and stems from an April 2024 precedential decision of the Federal Circuit affirming a district court’s final judgment that certain claims of several patents owned by Salix for a drug used to treat irritable bowel syndrome (IBS) and other ailments were invalid as obvious.

Pharmaceuticals 59

Pharmaceuticals Litigation 59

IP Watchdog

JULY 23, 2024

After filing 13 lawsuits in 2023 claiming trademark infringement, deceptive trade practices, and false advertising related to the pharmaceuticals Ozempic and Wegovy, Novo Nordisk—a 100-year-old pharmaceutical company with its origins in Denmark—is once again making headlines.

Pharmaceuticals 59

Pharmaceuticals Litigation 59

IP Watchdog

FEBRUARY 1, 2024

Department of Health and Human Services (HHS) made its initial offers to pharmaceutical companies pursuant to the Biden Administration’s Inflation Reduction Act of 2022 (IRA), which allows the U.S. Today, the U.S. Government to “negotiate” Medicare drug prices under a set framework based upon the amount of time a drug has spent on the market.

Pharmaceuticals 104

Pharmaceuticals Litigation 104

IP Watchdog

MAY 8, 2023

This week in Washington IP news, both houses of Congress are busy with hearings that touch on subjects relevant to IP. Both the Senate and House will be holding hearings on two hot-button issues: semiconductor supply chains and prescription drug pricing. Elsewhere, the USPTO is holding an AI inventorship listening session on the West Coast.

Pharmaceuticals 69

Pharmaceuticals 69

IP Watchdog

MARCH 9, 2022

The Initiative for Medicines, Access & Knowledge (I-MAK) has responded to a letter it received from Senator Thom Tillis (R-NC) in January asking the organization to address claims that its data on the effects of pharmaceutical patents on drug pricing is faulty. I-MAK’s view is that the U.S.

Pharmaceuticals 126

Pharmaceuticals 126

IP Watchdog

APRIL 29, 2024

The COVID-19 vaccine was quickly rolled out compared to other vaccines in the past and many pharmaceutical companies benefited financially. However, GSK contends their competitors, Pfizer Inc. and Pharmacia & Upjohn Co. LLC (collectively Pfizer) and BioNTech SE, BioNTech Manufacturing GMBH and BioNTech US Inc.

Manufacturing 111

Manufacturing Pharmaceuticals Technology Litigation 111

IP Watchdog

JANUARY 19, 2023

Patent and Trademark Office (USPTO) and the Food and Drug Administration (FDA) today jointly held an all-day listening session featuring speakers from patient advocacy and industry groups, academia, and brand and generic pharmaceutical companies who weighed in on the relationship between patents and affordable access to medicines.

Evidence 128

Evidence Pharmaceuticals 128

IP Watchdog

AUGUST 30, 2024

This week in Other Barks & Bites: The World Intellectual Property Office (WIPO) releases a list of the top technology clusters in the world; La Jolla Pharmaceuticals files lawsuit against USPTO to revive shock therapy patent; Romania joins the Unitary Patent System; "very demure, very mindful" trend leads to trademark drama.

Technology 59

Technology Pharmaceuticals 59

Insurance Journal

AUGUST 8, 2024

The third trial over claims that discontinued heartburn drug Zantac ended in a mistrial on Wednesday when jurors could not agree about whether pharmaceutical company Boehringer Ingelheim was responsible for an Illinois man’s cancer. Martin Gross alleged in his lawsuit …

Pharmaceuticals 59

Pharmaceuticals Manufacturing 59

IP Watchdog

APRIL 1, 2024

Court of Appeals for the Federal Circuit (CAFC) ruled in a precedential decision authored by Judge Prost on Monday that certain claims of Janssen Pharmaceuticals Inc.’s

Pharmaceuticals 52

Pharmaceuticals Litigation 52

IP Watchdog

OCTOBER 10, 2024

The letter sent last week was organized by Lawyers for Civil Justice (LCJ) and signed by some of the world’s largest and most well-known corporations, including all of the major internet platforms, pharmaceutical and automotive companies.

Litigation 64

Litigation Automotive Pharmaceuticals 64

IP Watchdog

APRIL 22, 2024

Vanda Pharmaceuticals filed the petition following the U.S. Supreme Court today denied a petition for certiorari seeking clarification from the Court on the proper standard for a showing of obviousness.

Pharmaceuticals 104

Pharmaceuticals Evidence 104

IP Watchdog

JANUARY 24, 2023

Last week, Novartis Pharmaceuticals followed through on its September 2022 promise that it would appeal the U.S. Court of Appeals for the Federal Circuit’s (CAFC’s) June 2022 decision invalidating its patent for a dosing regimen for its multiple sclerosis drug Gilenya to the U.S.

Pharmaceuticals 124

Pharmaceuticals Litigation 124

IP Watchdog

AUGUST 11, 2021

Believe it or not, a recent op-ed in the Washington Post written by Robin Feldman took the position that pharmaceutical companies should charge prices for their drugs that would surely guarantee that they go bankrupt.

Pharmaceuticals 144

Pharmaceuticals 144

IP Watchdog

FEBRUARY 6, 2023

Case law has defined prosecution laches as an affirmative defense against an infringement assertion. Specifically, the case law indicates a patent that is being asserted is unenforceable when the patentee caused an unreasonable and unexplained delay in prosecution of the patent. Symbol Tech v Lemelson Medical, No. 04-1451 (Fed.

Pharmaceuticals 69

Pharmaceuticals Case Law Technology 69

IP Watchdog

AUGUST 18, 2022

Court of Appeals for the Federal Circuit (CAFC) today affirmed a district court’s finding that Eagle Pharmaceuticals, Inc.’s s abbreviated new drug application (ANDA) does not infringe two patents owned by Par Pharmaceutical, Inc., In its third precedential patent decision this week, the U.S.

Pharmaceuticals 72

Pharmaceuticals Litigation 72

IP Watchdog

OCTOBER 20, 2022

The People’s Vaccine Alliance, a coalition of over 100 organizations, issued a statement this week alleging that the pharmaceutical industry is attempting to tighten its control of the world’s pandemic response plans.

Pharmaceuticals 81

Pharmaceuticals Manufacturing Technology Litigation 81

IP Watchdog

AUGUST 27, 2023

This past week, IPWatchdog was made aware of a petition for post-grant review (PGR) proceedings at the Patent Trial and Appeal Board (PTAB) that raises interesting arguments about allegedly inconsistent statements on patentability made during legal proceedings by pharmaceutical firm, Gilead Sciences.

Pharmaceuticals 52

Pharmaceuticals 52

IP Watchdog

MAY 12, 2023

This week in Other Barks & Bites: AI inventorship comments due, the United States Patent and Trademark Office (USPTO) seeks nominations to two advisory committees; Oprah’s company settles a trademark dispute with a podcast; and high-profile pharmaceutical company CEOs testify before the Senate on insulin prices.

Pharmaceuticals 102

Pharmaceuticals 102

IP Watchdog

AUGUST 6, 2021

Court of Appeals for the Federal Circuit (CAFC) on Thursday underscored its October 2020 ruling that generic company, Teva Pharmaceuticals, was liable for induced infringement of GlaxoSmithKline’s (GSK’s) patent directed to a method of treating Congestive Heart Failure (CHF) using carvedilol.

Pharmaceuticals 124

Pharmaceuticals Litigation 124

IP Watchdog

FEBRUARY 2, 2023

The key data being questioned is that of the Initiative for Medicines, Access & Knowledge (I-MAK), an advocacy organization that has become a “principal, go-to source” for data on the number of patents and patent applications covering pharmaceutical innovations.

Pharmaceuticals 119

Pharmaceuticals Technology 119

IP Watchdog

SEPTEMBER 15, 2023

This week in Other Barks & Bites: the CAFC issues a precedential ruling in a design patent win for Columbia Sportswear; the country’s biggest tech CEOs testify before Congress on the state of artificial intelligence (AI) in the United States; the Federal Trade Commission releases a policy statement charging that brand pharmaceutical companies (..)

Pharmaceuticals 59

Pharmaceuticals 59

IP Watchdog

FEBRUARY 8, 2024

Patents came up throughout the hearing as one barrier to lowering prescription drug prices, while pharmaceutical industry representatives underscored the cost of bringing innovative and life-saving drugs to market and the superior access Americans have to such drugs compared with other countries.

Pharmaceuticals 59

Pharmaceuticals Education 59

IP Watchdog

AUGUST 16, 2021

Court of Appeals for the Federal Circuit today issued two precedential decisions and one nonprecedential decision in cases involving Teva Pharmaceuticals and Eli Lilly, delivering wins and losses for each company.

Pharmaceuticals 119

Pharmaceuticals Litigation 119

IP Watchdog

SEPTEMBER 30, 2022

Court of Appeals for the Federal Circuit (CAFC) earlier today upheld a Patent Trial and Appeal Board (PTAB) decision finding that Mylan Pharmaceuticals, Inc. In its third precedential patent opinion this week, the U.S. failed to show that certain claims of Merck Sharp & Dohme Corp.’s

Pharmaceuticals 122

Pharmaceuticals Litigation 122